Thomas L. Skillman Joins BRI as the First Director of Research Technology

Seattle, WA

Benaroya Research Institute at Virginia Mason (BRI) recently named Thomas L. Skillman as BRI’s first Director of Research Technology. Skillman will collaborate with research staff on novel research programs with a technology emphasis including the design and management of the scientific computing infrastructure. This infrastructure will assist researchers in the management, analysis and sharing of their scientific data.

Skillman’s experience includes more than 20 years in research and development management including working with health science organizations, providing both strategic planning and operational leadership. He was previously a principal of Epigenomics and the first Senior Deputy Director of the HIV Statistical Center at Fred Hutchinson Cancer Research Center. He also provided business and information system leadership to two University of Washington start-up companies, Seattle Sensor Systems and Cardiac Mimetics, and maintains close connections to the UW eScience Institute. Skillman received an Executive MBA from the University of Washington as well as an MS in Computer Science and a BS in Physics, both from the University of Maryland.

“As our BRI scientists work to understand the function and dysfunction of the human immune system,” notes Skillman, “they increasingly rely on a growing volume of research data. Having the technology in place to measure, store, integrate and analyze this data is key to increasing the impact of their research.”

About Benaroya Research Institute at Virginia Mason

Benaroya Research Institute at Virginia Mason (BRI), founded in 1956, is an international leader in immune system and autoimmune disease research, translating discoveries to real-life applications. BRI employs more than 275 scientists, physician researchers and staff, supported in part by grants from the National Institutes of Health (NIH), the U.S. Department of Defense, JDRF, the Leona M. and Harry B. Helmsley Charitable Trust and others.

BRI also leads the Immune Tolerance Network (ITN), a research cooperative network funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. The ITN conducts international clinical trials to evaluate novel therapies for transplantation, allergy and autoimmune diseases as well as laboratory-based studies.

Visit or for more information about BRI, clinical studies and the more than 80 different types of autoimmune diseases. Visit for more information about ITN and clinical studies.



Learn the Latest

A sample printed newsletterSign up for our news & updates and learn the latest in the fight against autoimmune diseases.

Sign up today